Recent evidence suggests that inflammation was participated in the pathogenesis of PD, thus, to understand the potential mechanism of gut microbiota in the pathogenesis of Parkinson’s disease (PD), we performed a metagenomic analysis of fecal samples from PD patient and controls. Using a two-stage metagenome-wide association strategy, fecal DNA samples from 69 PD patients and 244 controls in three groups (comprising 66 spouses, 97 age-matched, and 81 normal samples, respectively) were analyzed, and differences between candidate gut microbiota and microbiota-associated epitopes (MEs) were compared. In the study, 27 candidate bacterial biomarkers and twenty-eight candidate epitope peptides were significantly different between the PD patients and control groups. Further, enriched 4 and 13 MEs in PD were positively associated with abnormal inflammatory indicators [neutrophil percentage (NEUT.1), monocyte count/percentage (MONO/MONO.1), white blood cell count (WBC)] and five candidate bacterial biomarkers (c_Actinobacteria, f_Bifidobacteriaceae, g_Bifidobacterium, o_Bifidobacteriales, p_Actinobacteria) from Actinobacteria phylum, and they were also positively associated with histidine degradation and proline biosynthesis pathways, respectively. Additionally, enriched 2 MEs and 1 ME in PD were positively associated with above inflammatory indicators and two bacteria (f_Lactobacillaceae, g_Lactobacillus) from Firmicutes phylum, and they were also positively associated with pyruvate fermentation to propanoate I and negatively associated with isopropanol biosynthesis, respectively. Of these MEs, two MEs from GROEL2, RPSC were derived from Mycobacterium tuberculosis, triggered the T cell immune response, as previously
INTRODUCTION

Parkinson’s disease (PD) is one of the most common neurodegenerative disorders worldwide, for which there is currently no complete cure (1). Besides its motor and cognitive symptoms, many patients also have gastrointestinal (GI) dysfunction preceding other symptoms, such as constipation and an extended time interval between defecations (2). A study using transgenic mice carrying human A53T-α-synuclein (α-syn) found that while signs of GI dysfunction were observed in the mice at 3 months of age, motor abnormalities and α-syn pathology were only observed 6 months later (3).

The increasing research interest in the gut–brain axis has led to many in-depth studies of the pathology and gut microbiota in PD. Several studies have indicated an association between GI inflammation and the accumulation of α-syn in the enteric nervous system of PD (4). Transplantation of the gut microbiota from PD-affected patients enhances motor impairments and inflammation, with inflammation possibly posing as a risk factor for PD (5). Furthermore, a number of studies have indicated that bacterial infection is also associated with a higher risk of neurodegeneration. For instance, it has been shown that Bacillus Calmette–Guérin vaccine can induce neuroprotection in a mouse model of PD (6). In addition, pathogenic genes involved in PD, such as PARK2, PINK1, and LRRK2, are thought to regulate innate immunity and relate to susceptibility to bacterial infection in the gut. These results indicate that the effect of dysfunction of the gut microbiota on the immune system plays an important role in PD (7).

An increasing number of findings confirm that gut microbiota-associated epitopes (MEs) do affect the immune system, contributing to abnormal inflammatory reactions and the pathological status of neurological diseases; thus, their relationship with PD needs to be further studied. Additionally, gut microbiota may also affect the nervous system via the metabolites it releases. Certain metabolites such as glutamate can function as excitatory neurotransmitters and cause excitatory responses (8, 9). To further investigate the alteration of the gut microbiota and its potential effects on immunity and metabolism in PD, we employed a two-stage shotgun metagenomic approach and analyzed the data using the Immune Epitope Database (IEDB) (10), according to previously developed methods (11). Therefore, in the present study, we recruited 69 PD patients, 81 healthy controls (HC), 66 spouses of PD patients (SP), and 97 age-matched healthy controls (NG) from the public database, with the latter two groups included to minimize the effects of lifestyle/diet and age/gender, respectively. Based on the metagenome-wide association analysis, we identified the PD-associated gut microbiota and predicted MEs and pathways that may be responsible for effects on immune function and pathology in PD.

MATERIAL AND METHODS

Subjects

The protocols of this study were approved by the Research Ethics Committee at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine. This study was registered in the China Clinical Trials Registry (ChiCTR) with registration number ChiCTR1800018493. Sixty-nine participants were enrolled from the Second Affiliated Hospital of Guangzhou University of Chinese Medicine from September 2018 to May 2019. Each participant was informed of the purpose of this study and signed a clearly stated consent form. All measurements were voluntary.

All patients (n = 69) were diagnosed with PD according to the diagnostic criteria proposed by the International Parkinson’s Disease and Movement Disorder Society in 2015 (12). Exclusion criteria for subjects with PD were as follows: (1) intake of probiotics or antibiotics within the last 3 months; (2) diagnosed with digestive system diseases such as inflammatory bowel disease, colitis, or colon cancer. Three control groups were used in this study. Firstly, the dataset for the HC group (n = 81) was included from another study (unpublished data). Secondly, the SP group (n = 66) was recruited as an internal control group to account for the influence of lifestyle and dietary factors on the gut microbiota. Thirdly, the dataset of an additional healthy control group, NG (n = 97), was included from a published database (13), and was used to account for the influence of age and gender. The same exclusion criteria were applied to the groups of healthy controls as were applied to the PD group.

Clinical Data Collection

Clinical data were collected via face-to-face interviews. The weight and height of each participant were measured and their body mass index (BMI) was calculated. Questionnaires concerning non-motor symptoms, including the Non-Motor Symptoms Scale (NMSS), Hamilton Depression Scale (HAM-D), Hamilton Anxiety Scale (HAM-A), Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE) and MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) were obtained from PD patients. In addition, 41 PD patients also received routine blood examination and assessment of the following inflammatory indicators: white
blood cell count (WBC); neutrophil count/percentage (NEUT/NEUT.1); lymphocyte (LYM); monocyte count/percentage (MONO/MONO.1); eosinophilia (EOSIN); basophils (BASO); red blood cell count (RBC); hemoglobin (Hb); hematocrit (HCT); mean red blood cell volume (MCV); mean cell hemoglobin (MCH); mean cell hemoglobin concentration (MCHC); red blood cell distribution width (RDW); PLT; MPV; PCT; and platelet distribution width (PDW). All clinical data were listed in Table 1.

**Fecal Sample Collection, DNA Extraction, and Sequencing**

Fecal DNA samples were typically collected at home using a QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany) and transferred to our hospital within 48 h and stored at -20°C. A total of 1 µg DNA per sample was used as the input material for the DNA sample preparations. Sequencing libraries were generated using a NEBNext Ultra DNA Library Prep Kit for Illumina (NEB, E7645S) according to the manufacturer’s recommendations, and index codes were added to attribute sequences to each sample. DNA concentration was measured by sonication to a size of 350 bp. Samples were sequenced using 150 bp paired-end reads on an Illumina HiSeq platform, on average, approximately 6 Gb read bases were generated per sample (Novogene Bioinformatics Technology, Beijing, China).

| TABLE 1 | Characteristics of the study subjects. |
|----------|----------------------------------------|
| Characteristics | PD group (n = 69) | HC group (n = 81) | P value (PD, HC) | SP group (n = 66) | NG Group (n = 97) | P value (PD, NG) |
| Age (years) | 58.1 (12.0) | 36.3 (11.2) | <0.001 | 59.0 (12.1) | 65.7 (9.3) | 0.608 |
| Female (n, %) | 28 (40.6) | 14 (17.3) | <0.01 | 41 (62.1) | 53 (54.6) | 0.103 |
| BMI (kg/m2) | 23.1 (2.91) | 23.3 (2.5) | 0.919 | 23.2 (3.3) | – | – |
| H&Y stage | 2.2 (0.55) | – | – | – | – | – |
| Age of onset (years) | 58.8 (7.3) | – | – | – | – | – |
| Disease duration (years) | 6.2 (4.5) | – | – | – | – | – |
| MDS_UPDRS | 53.3 (27.0) | – | – | – | – | – |
| MDS_UPDRS_P1 | 8.0 (5.2) | – | – | – | – | – |
| MDS_UPDRS_P2 | 11.1 (7.2) | – | – | – | – | – |
| MDS_UPDRS_P3 | 29.0 (16.5) | – | – | – | – | – |
| MDS_UPDRS_P4 | 2.2 (3.2) | – | – | – | – | – |
| HAMA | 10.1 (6.8) | – | – | – | – | – |
| HAMD | 7.1 (5.2) | – | – | – | – | – |
| MCI | 23.7 (3.7) | – | – | – | – | – |
| NMSS | 40.1 (26.2) | – | – | – | – | – |
| MMSE | 27.7 (2.7) | – | – | – | – | – |
| WBC | 6.3 (2.3) | – | – | – | – | – |
| NEUT.1 | 62.3 (12.6) | – | – | – | – | – |
| LYM | 26.9 (10.6) | – | – | – | – | – |
| MONO.1 | 7.1 (2.7) | – | – | – | – | – |
| EOSIN | 3.3 (5.3) | – | – | – | – | – |
| BASO | 0.4 (0.3) | – | – | – | – | – |
| NEUT | 4.1 (2.3) | – | – | – | – | – |
| LYM | 1.6 (0.6) | – | – | – | – | – |
| MONO | 0.4 (0.2) | – | – | – | – | – |
| EOSIN_COUNT | 0.2 (0.4) | – | – | – | – | – |
| BASO | 0.0 (0.0) | – | – | – | – | – |
| RBC | 4.5 (0.5) | – | – | – | – | – |
| Hb | 133.1 (11.2) | – | – | – | – | – |
| HCT | 40.1 (3.2) | – | – | – | – | – |
| MCV | 90.1 (6.4) | – | – | – | – | – |
| MCH | 29.9 (2.2) | – | – | – | – | – |
| MCHC | 331.6 (8.5) | – | – | – | – | – |
| RDW | 12.8 (0.7) | – | – | – | – | – |
| PLT | 215.1 (56.6) | – | – | – | – | – |
| MPV | 11.7 (1.2) | – | – | – | – | – |
| PCT | 0.2 (0.0) | – | – | – | – | – |
| PDW | 12.7 (2.8) | – | – | – | – | – |

PD, Parkinson’s disease; HC, healthy control; SP, spouse of PD patients; NG, normal group; BMI, body mass index; H&Y stage, Hoehn and Yahr stage; MDS-UPDRS, MDS-Unified Parkinson’s Disease Rating Scale; MDS-UPDRS_P1, non-motor experiences of daily living; MDS-UPDRS_P2, motor experiences of daily living; MDS-UPDRS_P3, motor examination; MDS-UPDRS_P4, motor complications; HAMA, Hamilton Anxiety Scale; HAMD, Hamilton Depression Scale; MoCA, Montreal Cognitive Assessment; NMSS, Non-Motor Symptoms Scale; MMSE, Mini-Mental State Examination; WBC, white blood cell count; NEUT/NEUT.1, neutrophil count/percentage; LYM, lymphocyte; MONO/MONO.1, monocyte count/ percentage; EOSIN, eosinophila; BASO, Basophils; RBC, Red blood cell count; Hb, hemoglobin; HCT, Hematocrit; MCV, Mean red blood cell volume; MCH, mean cell hemoglobin; MCHC, mean cell hemoglobin concentration; RDW, Red blood cell distribution width; PLT, platelet count; MPV, mean platelet volume; PCT, plateletcrit; PDW, platelet distribution width.

“-“: not available. Numbers are expressed as mean ± standard deviation. P < 0.05; significant differences; P > 0.05; no differences.
Raw Sequencing Data Preprocessing
Data from the whole metagenome were trimmed and human reads were filtered using KneadData software (https://bitbucket.org/biobakery/kneaddata) with the default parameters. Trimmomatic (trimmomatic-0.36-3; with the parameters: "SLIDINGWINDOW: 4:20 MINLEN: 50") (14) was used to remove low-quality reads and adaptor sequences, while bowtie2 (parameters: “–very-sensitive –dovetail”) (15) was used to perform an alignment to the hg37 genome and remove host reads. The corresponding data download path is "http://huttenhower.sph.harvard.edu/kneadData_databases/Homo_sapiens_hg37_and_human_contamination_Bowtie2_v0.1.tar.gz”. The remaining reads were aligned to the IEDB (10) to perform prediction and analysis of potential epitope peptides and T cell antigenic epitopes, after which the gut microbiota-associated epitope profile was generated (11). MetaPhIAn2 software (16) (using the default settings) was used to generate a metagenomic taxonomic profile for further analysis. Functional and pathway profiling was performed with HUMAnn2 (17) using the UniRef90 database with default settings.

Bioinformatic and Statistical Analysis
R software (version 3.1.0) was used for statistical analysis. The R function “adonis” (from the “vegan” package) was used to perform a permutation test between clinical parameters and the metagenomic taxonomic profile, while the “metaMDS” function was used to perform NMDS analysis. The inverse Simpson diversity index was measured using the “diversity” function (from the “vegan” package). Group differences in diversity and phylum-level profiles were analyzed using the Wilcoxon rank-sum test and the “boxplot” function was used to plot the results. Results with P < 0.05 were considered statistically significant. PD- or HC-enriched microbiota were identified from the taxonomic profile, functional profile, and gut microbiota-associated epitope profile, using the following methods: (1) the linear discriminant analysis (LDA) effect size (LEfSe) algorithm was used to identify taxonomic biomarkers (with LDA > 2.5); (2) The DESeq2 package was used to identify potential functional biomarkers (with P < 0.05, False Discovery Rate (FDR) < 0.05, and |deseq2.logfoldchange| > 0.58); (3) Epitope peptides are used to analyze the composition of gut microbiota at the functional level to predict the underlying immune function composition of gut microbiota, and the DESeq2 package was used to identify epitope biomarkers (with P < 0.05, FDR < 0.05, and |deseq2.logfoldchange| > 1). The Pearson correlation between clinical parameters and candidate biomarkers was calculated using the “cor.test()” function. Results with P < 0.05 and |correlation| > 0.2 were considered statistically significant. The same method was also used to analyze the correlation among different candidate biomarkers, and a heatmap was used to plot the results. Additionally, the “lm” function was used to calculate the regression between each clinical parameter and each candidate biomarker.

RESULTS
Basic Characteristics of the PD and Control Groups
A flow chart of the study design is shown (Figure 1). A total of 69 PD patients were recruited for the disease group, while 81 HC, 66 SP, and 97 NG subjects were recruited for the control groups. First, the PD group was compared with the HC group to screen for different gut microbiota between the two groups. Second, the SP group was used as the control group to eliminate the influence of environmental and dietary factors on gut microbiota. Finally, as significant differences in age and gender were detected between the PD and HC groups (P < 0.05), the NG group was included in this study to eliminate the influence of these two factors. The results showed that differences were not significant (P > 0.05) in the measured clinical indices in the PD and HC groups. The characteristics of the groups are summarized in Table 1.

Metagenome-Wide Association Study and Identification of Potential Taxonomic Bacterial Biomarkers
To understand whether the composition of the gut microbiota differed between the PD and control groups, firstly, we compared the Shannon and inverse Simpson diversity indexes between groups. The results showed that gut microbiota diversity was significantly increased in patients with PD compared with that in the other control groups (Figures 2A, B, P < 0.05). Additionally, we further performed species-level non-metric multi-dimensional scaling (NMDS) analysis: the results showed that PD group was distinct from control samples (Figure 2C, Supplementary Image 1, P < 0.05). Meanwhile, there were 93 candidate bacterial biomarkers found in the metagenome-wide association study (MWAS) between the PD and HC groups. In contrast, for the SP and NG groups, we found that 66 candidate biomarkers were no longer significant, while the remaining 27 candidate biomarkers were considered to be important differential bacteria in PD. Among these, 12 robust bacterial biomarkers belonged to Actinobacteria phylum, 2 robust bacterial biomarkers belonged to Bacteroidetes phylum, 8 robust bacterial biomarkers belonged to Firmicutes phylum, and 5 robust bacterial biomarkers belonged to Proteobacteria phylum (Supplementary Image 2, P < 0.05). Furthermore, gender had a limited influence on these selected biomarkers, with no significant difference found between male and female samples (Supplementary Image 3, P > 0.05). Taken together, our findings indicated that using multiple control groups can help to identify accurate PD-related biomarkers. A set of robust bacterial biomarkers were selected, which are listed in Table S1 (FDR < 0.05).

Correlation Between Clinical Indicators in PD Patients and Candidate Bacterial Biomarkers
One of the key functions of the gut microbiota is to know its role in affecting the host’s immune system (18). Therefore, we
FIGURE 1 | Study design. A two-stage (discovery and validate) MWAS analysis as used to identify potential bacterial biomarkers for PD. PD, Parkinson’s disease; SP, spouse of PD patients; NG, normal group; HC, healthy control. The SP group was used to account for the influence of lifestyle and dietary factors. The NG group was used to evaluate the effects of age and gender. Robust bacteria/epitope/pathway biomarkers were identified and their correlations with clinical parameters were evaluated.
performed linear regressions on PD patients data between each of the 27 selected bacterial biomarkers and inflammatory indicators. The results found that five candidate bacterial biomarkers (c_Actinobacteria, f_Bifidobacteriaceae, g_Bifidobacterium, o_Bifidobacteriales, p_Actinobacteria) belonged to Actinobacteria phylum have significant correlations with clinical indicators of inflammation including MONO.1 and NEUT.1, and two candidate bacterial biomarkers (f_Lactobacillaceae, g_Lactobacillus) belonged to Firmicutes phylum have significant correlations with MONO (Figure 3, Table S2, P < 0.05).

Identification of MEs in the PD and Control Groups

To understand the possible immune functions of the gut microbiota, we predicted the composition of gut MEs in PD patients. A total of 28 significant epitope biomarker candidates were found, among which 25 were PD-enriched, while three were HC-enriched (Figure 4, FDR < 0.05). The PD-enriched MEs were very similar to peptides from proteins, for example, one ME was derived from 30S ribosomal protein L16 (RPL16) from Chlamydia trachomatis; one ME from threonine–tRNA ligase 1, cytoplasmic (TARS1), derived from Mus musculus (mouse); one ME from cellulase domain-containing protein (PADG_07615), derived from Paracoccidioides brasiliensis; and one ME from 30S ribosomal protein S16 (RPS16), derived from Mycobacterium smegmatis. Furthermore, there were four MEs derived from Homo sapiens (human): one from glucose-6-phosphate isomerase (GPI); one from dihydroprymidinase-related protein 2 (DPYSL2); one from succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial (SDHA); and one from aldehyde dehydrogenase family 3 member A2 (ALDH3A2). In addition, there were five MEs derived from Mycobacterium leprae: three from 65-kDa antigen (RMLB); and two from chaperone protein DnaK (DNAK). There were 10 MEs derived from Mycobacterium tuberculosis, namely: one from 30S ribosomal protein S14 type Z (RPSZ); one from ribonucleoside-diphosphate reductase subunit alpha (NRDE); one from UPF0051 protein Rv1461 (RV1461); one from malate dehydrogenase (MDH); one from dTDP-glucose 4,6-dehydratase (RMLB); one from isoleucine–tRNA ligase (ILES); one from 30S ribosomal protein S3 (RPS3); one from 30S ribosomal protein S10 (RPS10); one from 30S ribosomal protein S12 (RPS12); one from GTPase Era (ERA); and two from 60-kDa chaperonin 2 (GROEL2). Finally, the three HC-enriched MEs were also similar to peptides from proteins: one ME from purine nucleoside phosphorylase (PNP), derived from Rattus norvegicus (rat); and two MEs from glutamate dehydrogenase (GDH), derived from Trypanosoma cruzi. The distribution and origin of all epitope peptides are shown in Table S3.

Gut MEs Correlate With Inflammatory Cytokines and Actinobacteria/Firmicutes Phylum Bacteria in PD Patients

In order to investigate the relationship between differential MEs and gut microbiota composition or key clinical inflammatory indicators, we performed the linear regression between the 28 potential epitope biomarkers and inflammatory indicators and further evaluated the Spearman correlation between the selected epitope biomarkers and 27 bacterial biomarkers. The results showed that 16 potential epitopes enriched in PD were associated with MONO.1, NEUT.1 and WBC and also significantly positively correlated with above 5 Actinobacteria phylum candidate biomarkers (Figure 5, Table S4, P < 0.05), and 6 potential epitopes enriched in PD were associated with MONO.1, NEUT.1 and also positively correlated with above two Firmicutes phylum candidate bacteria (Figure 5, Table S5, P < 0.05).

Functional Pathways Correlate With Actinobacteria/Firmicutes Phylum Associated MEs

We performed HUMAnN2 to identify significant functional pathways for gut microbiota in the PD group. The following
four potential pathway biomarkers were found to be increased: L-histidine degradation I; pyruvate fermentation to propanoate I; isopropanol biosynthesis; and L-proline biosynthesis II (from arginine) (Figure 6A, $P < 0.05$). For five bacteria belonged to Actinobacteria phylum, the corresponding results showed that c_Actinobacteria, f_Bifidobacteriaceae, g_Bifidobacterium, o_Bifidobacteriales, and p_Actinobacteria was positively correlated with L-proline biosynthesis II (from arginine), and c_Actinobacteria, and p_Actinobacteria was also positively correlated with L-histidine degradation I. Additionally, for two bacteria belonged to Firmicutes phylum, f_Lactobacillaceae was positively correlated with pyruvate fermentation to propanoate I, and g_Lactobacillus was negatively correlated with isopropanol biosynthesis. Meanwhile, significant correlations between these four pathways and potential MEs were performed, and the results showed that 13 MEs, 23MEs, 1ME, and 7MEs were significantly correlated with the L-histidine degradation I, L-proline biosynthesis II (from arginine), isopropanol biosynthesis, and pyruvate fermentation to propanoate I, respectively (Figures 6B–E, Table S6, $P < 0.05$). Further, we found that 4/13 and 13/23 MEs were belonged to 16 MEs that correlated with the inflammation indicators and these five bacteria from Actinobacteria phylum, and 1/1 ME and 2/7 MEs were belonged to 6 MEs that correlated with the inflammation indicators and two bacteria from Firmicutes phylum (Table 2, $P < 0.05$).
DISCUSSION

In this study, we found 27 candidate bacterial biomarkers for PD, of which 26 were increased while only one (Roseburia) was decreased in the PD group (Table S1). Among these biomarkers, six have been reported in earlier studies. Five of these previously reported bacterial biomarkers are consistent with our results, namely Roseburia (19, 20), Bifidobacteriaceae (19, 21), Bifidobacterium (19, 20), Desulfovibrionaceae (21), and Lactobacillaceae (20). The remaining one bacterial biomarker, Lactobacillus, was increased in the PD group in our results, which is consistent with results from some previous studies (20, 22), while not with those from two studies using Chinese patients (23). These contradictory findings might be attributable to regional and dietary differences in the PD patients and controls being studied. Our participants were mainly from South China, while the participants in the other two contradictory studies were from Northeast China and East China respectively (24). In addition to the biomarkers identified in the current study, a further 13 have been reported previously. However, these were not at the same taxonomic level as those described here, but were reported at either a higher or lower taxonomic level, including: Alistipes (25); Rikenellaceae (25); Deltaproteobacteria (21); Desulfovibrionales (21); Bilophila (21); Desulfovibrio (21); Actinobacteria (phylum and class) (19, 20); Bifidobacteriales (19, 20); Bifidobacterium dentium (19, 20); Bifidobacterium longum (19, 20); and unclassified strain in Bifidobacterium dentium (19, 20); and unclassified strain in Bifidobacterium longum (19, 20). Nevertheless, we found that all 13 of these biomarkers were increased in the PD group, consistent with the results of earlier studies. The remaining eight biomarkers were identified for the first time in this study, comprising: Coriobacterales; Coriobacteriaceae; Collinsella; Oscillospiraceae; Oscillibacter; unclassified species in Oscillibacter; Subdoligranulum sp_4_3_54A2FAA; and t-GCF_000238635. A previous report showed that Collinsella (related markers: Coriobacterales and Coriobacteriaceae) was increased in other diseases, such as rheumatoid arthritis and type 2 diabetes (26), with a role for Collinsella in altering gut permeability and disease severity confirmed in experimental arthritis (27). Oscillibacter (related markers: Oscillospiraceae, Oscillibacter, and unclassified species in Oscillibacter) was reported to be related to diet-induced weight loss (28). Subdoligranulum (related markers: Subdoligranulum sp_4_3_54A2FAA, and t-GCF_000238635) was shown to be associated with constipation, a common symptom of PD. Taken together, these potential bacterial biomarkers may play important roles in PD, so the mechanisms through which these bacteria affect PD-related processes need to be further explored.

Intestinal dysfunction in PD may occur many years earlier than other symptoms, indicating that neurodegeneration may start in the gut and then begin later in the brain via the gut–brain axis. Gut microbiota can trigger the accumulation of α-synuclein and serve as a target for the diagnosis, treatment, and monitoring of disease progression in PD (29). Notably, a recent study showed that enteric inflammation plays an important role in PD pathogenesis (30). In the present study, we analyzed correlations between 27 gut microbiota biomarkers and clinical indicators in PD patients, and found a number of significant
results. Interestingly, among the biomarkers from the four bacterial phyla, the highest abundance *Actinobacteria* phylum bacterial biomarkers and several biomarkers under this taxonomic level (c *Actinobacteria*, f *Bifidobacteriaceae*, g *Bifidobacterium*, o *Bifidobacteriales*) were positively correlated with inflammatory indicators, such as MONO, MONO.1, and NEUT, and f *Lactobacillaceae* and g *Lactobacillus* belonged to Firmicutes phylum were also positively correlated with MONO (Table S2, Figure 3). These results demonstrate that alterations to the gut microbiota and the inflammatory response play significant roles in the pathogenesis of PD. Previously, Wang et al. reported that the richness of MEs is associated with an elevated gut microbiota and gut Immunoglobulin A (IgA) level in patients with autism (11), which suggests that altered MEs may trigger abnormal immune function. In fact, more than 500000 MEs in the IEDB database are associated with adaptive immunity, which may cause a specific B-cell or T-cell response and participate in disease development. Therefore, in the present study, we identified that 25 MEs and three MEs were enriched in the PD and HC groups, respectively (Table S3, Figure 4). Of the PD-enriched MEs, 16 MEs were found related to inflammatory indicators and increased abundance of the 5 candidate biomarkers from *Actinobacteria* phylum, and 6 MEs were found related to inflammatory indicators and increased abundance of the 2 candidate biomarkers from *Firmicutes* phylum, suggesting that the gut microbiota may cause changes in the inflammatory response via alterations to MEs. This in turn may influence immune function and contribute to PD-related processes (Tables S4 and S5).

Furthermore, to explore whether above 16 MEs that correlated with 5 bacteria from *Actinobacteria* phylum and inflammation markers were involved in PD pathogenesis mediated by the metabolic pathways, it was important to carry out a microbiome study at the functional level. The results showed that L-histidine degradation I and L-proline biosynthesis II from arginine enriched in the gut microbiota of the PD group were positively associated with 4 and 13 MEs, respectively when comparing with the control group (Table 2). Histidine can be degraded to glutamate and thus cause changes in glutamate concentration in the cell. Additionally, glutamate and arginine are precursors to the formation of proline, so the metabolic pathways might be altered in PD patients.
pathway that promotes glutamate by arginine also further increases glutamate accumulation (31). In this study, these two enriched pathways may have indirectly caused an elevation in the concentration of glutamate and L-proline in the gut of PD patients, which is consistent with previous finding of PD disease (32). Glutamate functions as an excitatory neurotransmitter and can cause an excitatory response when it binds to its receptor, so the extracellular concentration of
glutamate should remain low to maintain a healthy state (8). A higher extracellular concentration of glutamate can cause excitotoxicity, leading to malfunction of the neuron and cell death; this process has been associated with neurological and psychiatric diseases (8, 33). It is well known that inflammation can induce glutamate excitotoxicity (4). Interesting, among the MEs associated with these pathways, 11 of them are originated from *M. tuberculosis*, which has previously been associated with impaired innate defense mechanisms, chronic inflammation, and increased susceptibility to PD (34). In these MEs, two altered MEs have been found to be associated with immune function: ADPVKVTRSLQNAASIAGL from GROEL binds to human leukocyte antigen(HLA)-DR3 and restricts T cell responses (35); ERTDRVRVDIHTARP1G1 from RPS6 binds to major histocompatibility complex (MHC) class II, which is necessary for T cell recognition (36). Additionally, two of the significantly increased MEs are from *M. leprae*, an intracellular pathogen that commonly causes the chronic inflammatory disease leprosy. Recent research has found that *M. leprae* can invade nerve sheath cells, causing inflammatory reactions that lead to neuronal damage and neurodegeneration. The affinity of this pathogen for nerve cells increases the occurrence not only of leprosy, but potentially also of other neurological diseases such as PD, in which it may exert a crucial influence on PD-related pathogenesis (37). Moreover, the isopropanol biosynthesis pathway was significantly increased, while pyruvate fermentation to propionate I pathway was significantly decreased in the gut microbiota of the PD group and both of them were positively associated with 1 ME and 2 MEs among the 6 MEs that correlated with two bacteria from Firmicutes and inflammation markers, respectively (*Table 2*). Isopropanol is an effective central nervous system inhibitor, which has a great influence on the brain (38). Propionic acid is one of the common short chain fatty acids, which can protect the integrity of intestinal mucosa (39). Thus, in the study, alteration of these two pathways may increase the isopropanol level and decrease the propionic acid production, which may cause damage to the nervous system and promote intestinal permeability leading to leaky intestines, respectively. A recent studies have shown that WBCs are key blood immune cells that release pro-inflammatory cytokines, and that neutrophils account for 50% to 70% of the WBCs are key blood immune cells that release pro-inflammatory cytokines, and that neutrophils account for 50% to 70% of the

![Table 2](image-url)

**Table 2 | Actinobacteria/Firmicutes phylum and inflammatory markers associated epitopes in PD were significantly correlated with pathways enriched in PD.**

| PD Group | Pathways | MEs | Inflammatory biomarkers | Proteins | P value | Correlation | From |
|----------|----------|-----|------------------------|----------|---------|-------------|------|
| Actinobacteria phylum | L-histidine degradation I | LDGI\-GPEGMSRPEVEAEAV | NEUT.1, WBC | DPYSL2 | 9.36E-05 | 0.452806 | Homo sapiens |
| | | CGPRAVRYKFGCLR | NEUT.1, WBC | RPSZ | 0.020310 | 0.278889 | Mycobacterium leprae |
| | | AGOVAVIKAGAATVELKRI | MONO | RML65 | 0.010781 | 0.305162 | Mycobacterium tuberculosis |
| | | ADMLVRAWRVSYSYGRATISN | MONO.1, NEUT.1, WBC | RMLB | 0.035289 | 0.253884 | |
| Firmicutes phylum | L-proline biosynthesis II from arginine | LDLI\-GPEGMSRPEVEAEAV | NEUT.1, WBC | DPYSL2 | 0.00025 | 0.427394 | Homo sapiens |
| | | NVDRTIRSVHMGSDW45 | NEUT.1, WBC | DNAK | 0.000259 | 0.426357 | Mycobacterium leprae |
| | | AGOVAVIKAGAATVELKRI | MONO | RML65 | 2.89E-08 | 0.609702 | Mycobacterium tuberculosis |
| | | CGPRAVRYKFGCLR | NEUT.1, WBC | RPSZ | 2.33E-07 | 0.575328 | |
| | | AGOVAVIKAGAATVELKRI | MONO | RML65 | 2.33E-07 | 0.575328 | |
| | | ADMLVRAWRVSYSYGRATISN | MONO.1, NEUT.1, WBC | RMLB | 8.21E-07 | 0.553281 | |
| | | TEVEKRIH-RIEDVARNAK | NEUT.1, WBC | RML65 | 4.60E-05 | 0.470052 | |
| | | DAMRVFLMASPILGONIV | NEUT.1, WBC | ILE5 | 0.002666 | 0.425705 | |
| | | HSDDFQILVDPTGHRPRT | NEUT.1 | ERA | 0.000819 | 0.393644 | |
| | | ERTDRVRVDIHTARP1G1 | NEUT.1, WBC | RPS6 | 0.001324 | 0.378935 | |
| | | RYTQINWSNVNVNL | NEUT.1, WBC | RV1461 | 0.005517 | 0.330683 | |
| | | ADPKVKTRSLQNAASIAGL | NEUT.1, WBC | GROEL2 | 0.009855 | 0.30871 | |
| | | | | | | | |
| | Isopropanol biosynthesis | L-proline biosynthesis II from arginine | LDLI\-GPEGMSRPEVEAEAV | NEUT.1, WBC | DPYSL2 | 4.50E-05 | 0.265568 | Homo sapiens |
| | | ADMLVRAWRVSYSYGRATISN | NEUT.1, WBC | RMLB | 5.42E-06 | 0.257598 | Mycobacterium tuberculosis |

Frontiers in Immunology | www.frontiersin.org 11 July 2021 | Volume 12 | Article 632482
PD (42). Taken together, gut microbiota composition may produce epitopes, although correlations between some epitopes from these species and immunity has not been reported to date, the results of this study suggest that peptides from these proteins may play an important role in immunity in PD patients. This further indicates that the potentially dominant bacteria of the Actinobacteria phylum (c_Actinobacteria, f_Bifidobacteriaceae, g_Bifidobacterium, o_Bifidobacteriales, p_Actinobacteria) and Firmicutes phylum (f_Lactobacillaceae, g_Lactobacillus) may exert effects on immunity via these candidate MEs.

In all, in the present study, we analyzed a large number of samples from PD patients and healthy controls. We also recruited the SP and NG groups to minimize the influence of lifestyle factors, diet, gender, and age on the analysis of gut microbiota related to PD. Using various correlational and functional analyses, we found that altered MEs were significantly correlated with abnormal inflammation and biosynthesis of glutamate and propanoate. Thus, we proposed a model for gut MEs in PD pathogenesis according to these findings. We speculated that decreased abundance of propanoate may cause the increased intestinal permeability to deteriorate the normal gut permeability and generate “leaky gut”. Then inflammation and alpha-synuclein caused by the imbalance of the intestinal flora can affect the nerve function through the

![FIGURE 7](image-url)
reverse transmission of the intestine-brain axis. In addition, glutamate may travel through the “leaky gut” and function as neurotransmitter to cause excitotoxicity, and isopropanol may cause abnormal nervous system function (Figure 7). Taken together, these results suggested that altered intestinal MEs may aggravate the pathology of PD, and may be potential biomarkers of PD.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: China National GeneBank [https://db.cngb.org/search/project/CNP0001697/].

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

WP and XL conceived and designed the study. ZhuoL, GL, ZheL, and BW performed experiments and were major contributors in writing the manuscript, they were co-first authors. EL, XQ, JG, ZX, CZ, and XS made significant contributions to acquisition and analysis of data. QS, YZ, WC, XS, QC, YX, YC, and MW performed the statistical analysis. WP and XL revised the manuscript critically for important intellectual content. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by internal unrestricted research grant E473 to ZhuoL, Youth Program of National Natural Science Foundation of China (Grant No.: 82004459) and Natural Science Foundation of Guangdong Province, China (Grant No.: 2018A030310521).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.632482/full#supplementary-material

REFERENCES

1. Vasili E, Dominguez-Mejide A, Outeiro TF. Spreading of α-Synuclein and Tau: A Systematic Comparison of Parkinson’s Disease. Front Mol Neurosci (2019) 12:107. doi: 10.3389/fnmol.2019.00107
2. Suzuki K, Fujita H, Matsubara T, Hirata K. Non-Motor Symptoms in Postural Instability/Gait Difficulty Subtype in the Early Stage of Parkinson’s Disease. Eur J Neurol (2019) 26(3):e37. doi: 10.1111/ene.13828
3. Rota L, Pellegrini C, Benvenuti L, Antonioli L, Fornai M, Blandizzi C, et al. Constipation, Deficit in Colon Constructions and Alpha-Synuclein Inclusions Within the Colon Precede Motor Abnormalities and Neurodegeneration in the Central Nervous System in a Mouse Model of Alpha-Synucleinopathy. Transl Neurodegener (2019) 8:5. doi: 10.1186/s40035-019-0146-z
4. Chen QQ, Haikal C, Li W, Li YJ. Gut Inflammation in Association With Pathogenesis of Parkinson’s Disease. Front Mol Neurosci (2019) 12:218. doi: 10.3389/fnmol.2019.00218
5. Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Gut Microbiota Regulate Motor Deficits and Neuronflammation in a Model of Parkinson’s Disease. Cell (2016) 167(6):1469–80.e1412. doi: 10.1016/j.cell.2016.11.018
6. Kulkarni S, Mukherjee S, Pandey A, Dahake R, Padmanabhan U, Chowdhary AS. Bacillus Calmette-Guerin Confers Neuroprotection in a Murine Model of Japanese Encephalitis. Neuroimmunomodulation (2016) 23(3–4):278–86. doi: 10.1159/000452171
7. Chia SJ, Tan EK, Chao XY. Historical Perspective: Models of Parkinson’s Disease. Int J Mol Sci (2020) 21(7):2464. doi: 10.3390/ijms21072464
8. Olloquequi J, Cornejo-Cordova E, Verduguer E, Soriano FX, Birvinyat O, Auladell C, et al. Excitotoxicity in the Pathogenesis of Neurological and Psychiatric Disorders: Therapeutic Implications. J Psychopharmacol (2018) 32(3):265–73. doi: 10.1177/0269881118754680
9. Reiner A, Levitz J. Glutamatergic Signaling in the Central Nervous System: Ionotropic and Metabotropic Receptors in Concert. Neuron (2018) 98(6):1080–98. doi: 10.1016/j.neuron.2018.05.018
10. Vita R, Overton JA, Greenbaum JA, Ponomarenko J, Clark JD, Cantrell JR, et al. The Immune Epitope Database (IEDB) 3.0. Nucleic Acids Res (2015) 43(Database issue):D405–412. doi: 10.1093/nar/gku938
11. Wang M, Zhou J, He F, Cai C, Wang H, Yang Y, et al. Alteration of Gut Microbiota-Associated Epitopes in Children With Autism Spectrum Disorders. Brain Behav Immun (2019) 75:192–9. doi: 10.1016/j.bbi.2018.10.006
12. Postuma RB, Berg D, Stern M, Poewe W, Oertel W, et al. MDS Clinical Diagnostic Criteria for Parkinson’s Disease. Mov Disord (2015) 30(12):1591–601. doi: 10.1002/mds.26242
13. Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, et al. The Gut Microbiome in Atherosclerotic Cardiovascular Disease. Nat Commun (2017) 8(1):845. doi: 10.1038/s41467-017-00900-1
14. Bolger AM, Lohse M, Usadel B. Trimmomatic: A Flexible Trimmer for Illumina Sequence Data. Bioinformatics (2014) 30(15):2114–20. doi: 10.1093/bioinformatics/btu170
15. Langmead B, Salzberg SL. Fast Gapped-Read Alignment With Bowtie 2. Nature Methods (2012) 9(4):357–9. doi: 10.1038/nmeth.1923
16. Truong DT, Franzosa EA, Tickle TL, Schirmer G, Weingart G, Pasolli E, et al. Metaphlan2 for Enhanced Metagenomic Taxonomic Profiling. Nature Methods (2015) 12(10):902–3. doi: 10.1038/nmeth.3589
17. Franzosa EA, McIver LJ, Rahnavard G, Thompson LR, Schirmer M, Weingart G, et al. Species-Level Functional Profiling of Metagenomes and Metatranscriptomes. Nature Methods (2018) 15(11):962–8. doi: 10.1038/s41592-018-0176-y
18. Guarnieri F, Malagelada JR. Gut Flora in Health and Disease. Lancet (2003) 361(9356):512–9. doi: 10.1016/S0140-6736(03)12489-0
19. Aho VTE, Pereira PAB, Voutilainen S, Paulin L, Pekkonen E, Auvinen P, et al. Gut Microbiota in Parkinson’s Disease: Temporal Stability and Relations to Disease Progression. EBioMedicine (2019) 44:691–707. doi: 10.1016/j.ebiom.2019.05.064
20. Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, et al. Parkinson’s Disease and Parkinson’s Disease Medications Have Distinct Signatures of the Gut Microbiome. Mov Disord (2017) 32(5):739–49. doi: 10.1002/mds.26942
21. Lin A, Zheng W, He Y, Tang W, Wei X, He R, et al. Gut Microbiota With Parkinson’s Disease in Southern China. Parkinsonism Relat Disord (2018) 53:82–8. doi: 10.1016/j.parkreldis.2018.05.007
22. Lin CH, Chen CC, Chiang HL, Liu JM, Chang CM, Lu TP, et al. Altered Gut Microbiota and Gut Epithelial Promiscuous T Cell Epitopes in the Proteome of Mycobacterium Bovis. Microb Genom (2016) 2(8):e000071. doi: 10.1099/mgen.0.000071
23. Lin A, Taneya V, van Meijgaard KE, Zanelli A, Abou-Zeid C, Thele JE, et al. Identification of HLA Class II-Restricted Determinants of Mycobacterium Tuberculosis-Derived Proteins by Using HLA-Transgenic, Class II-Deficient Mice. Proc Natl Acad Sci USA (1998) 95(18):10797–802. doi: 10.1073/pnas.95.18.10797
24. Farrell D, Jones G, Pirson C, Malone K, Rue-Albrecht K, Chubb AJ, et al. Integrated Computational Prediction and Experimental Validation Identifies Promiscuous T Cell Epitopes in the Proteome of Mycobacterium Bovis. Proc Natl Acad Sci USA (2016) 113(40):10948–53. doi: 10.1073/pnas.1611087113
25. Bedarf JR, Hildebrand F, Coelho LP, Sunagawa S, Bahram M, Goeser F, et al. Composition, Functional Implications of Microbial and Viral Gut Metagenome Changes in Parkinson’s Disease Patients. Gut (2018) 70:194. doi: 10.1136/gutjnl-2018-316844
26. Lambeth SM, Carson T, Lowe J, Ramaraj T, Leff JW, Luo L, et al. Composition, Diversity and Abundance of Gut Microbiome in Prediabetes and Type 2 Diabetes. J Diabetes Obes (2015) 2(3):1–7. doi: 10.15436/2376-0949.15.031
27. Shin CH, Choi CH, Liu FC, Lin TY, Huang WY, Wang YC, et al. Association Between Tuberculosis and Parkinson Disease: A Nationwide, Population-Based Cohort Study. Med (Baltimore) (2016) 95(8):e22883. doi: 10.1097/MD.0000000000002283
28. Chakraborty D, Mohite GM, Krishnamoorthy J, Gayen N, Nehra S, Navalkar A, et al. Lipopolysaccharide From Gut Microbiota Modulates α-Synuclein Aggregation and Alters its Biological Function. ACS Chem Neurosci (2019) 10(5):229–36. doi: 10.1021/acschemneuro.8b00733
29. Perez-Pardo P, Dodiya HB, Engen PA, Forsyth CB, Huschens AM, Shaik M, et al. Role of TLR4 in the Gut-Brain Axis in Parkinson’s Disease: A Translational Study From Men to Mice. Gut (2019) 68(5):829–43. doi: 10.1136/gutjnl-2018-316844
30. Fichman Y, Gerdes SY, Kovacs H, Szabados L, Zilberstein A, Csonka LN. Evolution of Proline Biosynthesis: Enzymology, Bioinformatics, Genetics, and Transcriptional Regulation. Biochim Biophys Acta Rev Microbiol (2015) 90(4):1065–99. doi: 10.1111/bvr.12146
31. Mironova YS, Zhukova IA, Zhukova NG, Alihrova VM, Izhboldina OP, Latypova AV. Parkinson’s Disease and Glutamate Excitotoxicity. Zh Nevrol Psikhiatr Im S S Korsakov (2018) 118(6. Vyp. 2):50–4. doi: 10.17116/jnervo201811806250
32. Ribeiro FM, Vieira LB, Pires RG, Olmo RP, Ferguson SS. Metabolic Glutamate Receptors and Neurodegenerative Diseases. Pharmacol Res (2017) 115:79–91. doi: 10.1016/j.phrs.2016.11.013
33. Shen CH, Chou CH, Liu FC, Lin TY, Huang WY, Wang YC, et al. Association Between Tuberculosis and Parkinson Disease: A Nationwide, Population-Based Cohort Study. Med (Baltimore) (2016) 95(8):e22883. doi: 10.1097/MD.0000000000002283
34. Geluk A, Taneya V, van Meijgaard KE, Zanelli A, Abou-Zeid C, Thele JE, et al. Identification of HLA Class II-Restricted Determinants of Mycobacterium Tuberculosis-Derived Proteins by Using HLA-Transgenic, Class II-Deficient Mice. Proc Natl Acad Sci USA (1998) 95(18):10797–802. doi: 10.1073/pnas.95.18.10797
35. Farrell D, Jones G, Pirson C, Malone K, Rue-Albrecht K, Chubb AJ, et al. Integrated Computational Prediction and Experimental Validation Identifies Promiscuous T Cell Epitopes in the Proteome of Mycobacterium Bovis. Microb Genom (2016) 2(8):e000071. doi: 10.1099/mgen.0.000071
36. Hess S, Rambukkana A. Cell Biology of Intracellular Adaptation of Mycobacterium Leprae in the Peripheral Nervous System. Microbiol Spectr (2019) 7(4):247–66. doi: 10.1128/microbiolspec.BAI-0020-2019
37. Mylter TT, Wasserman GS, Watson WA, Knapp JF. Two-Week-Old Infant With Isopropanol Intoxication. Pediatr Emerg Care (1993) 9(3):146–8. doi: 10.1097/00006569-199306000-00007
38. Velasquez-Manoff M. Gut Microbiome: The Peacekeepers. Nature (2015) 518(7543):53–11. doi: 10.1038/51853a
39. Umehara T, Oka H, Nakahara A, Matsuno H, Murakami H. Differential Leukocyte Count Is Associated With Clinical Phenotype in Parkinson’s Disease. J Neurol Sci (2020) 409:116638. doi: 10.1016/j.jns.2019.116638
40. Tsai T, Bioy J, Chan J, Min W, Gunebaum E. Use of Induced Pluripotent Stem Cells to Investigate the Effects of Purine Nucleoside Phosphorylase Deficiency on Neuronal Development. LymphoSign J (2018) 5:49–56. doi: 10.14785/lymphosign-2018-0003
41. Blaylock RL. Parkinson’s Disease: Microglial/Macrophage-Induced Immunoexcitotoxicity as a Central Mechanism of Neurodegeneration. Surg Neurol Int (2017) 8:65. doi: 10.4103/sni.sni_441_16

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Li, Li, Li, Wu, Luo, Qiu, Guo, Xiu, Zheng, Su, Zeng, Chan, Su, Cai, Xu, Chen, Wang, Poon and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.